Promising New Drug for Migraine Prevention

A new phase 2 trial of ALD403, a humanized monoclonal antibody directed against calcitonin gene-related peptide (CGRO) showed that the drug was safe and effective. Although preliminary, the results are promising, said lead author, David W. Dodick, professor,...
Subscribe To Our Weekly Newsletter

Subscribe To Our Weekly Newsletter

Get a weekly digest of our posts straight to your inbox! We promise, no spam ever.

You have Successfully Subscribed!

Pin It on Pinterest